atugen and Sankyo Sign Multi-Year Contract Research Agreement

20-May-2004
Berlin, Germany. atugen AG announced that it has signed a multi-year contract research agreement with Sankyo Co. Ltd, one of Japan's leading pharmaceutical companies. Both companies have already successfully collaborated on a number of proprietary molecular targets that Sankyo has discovered in different disease areas. atugen will now use its gene silencing technologies, including siRNA, GeneBlocs®, delivery reagents and functional assays to validate an undisclosed number of Sankyo targets No financial details of the research agreement are being disclosed. "We are delighted to be starting on this major research project with Sankyo. We have already worked with the company on a pilot study so our two research teams have established a working routine," said Dr. Klaus Giese, atugen´s Chief Scientific Officer and Vice President of Research. "Our knowledge and experience in target validation and disease pathways will save considerable time for Sankyo by validating targets that will lead to the most viable drugs."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances